Oxurion NV

Biotechnology Research • Leuven, Flemish Region, Belgium • 21-50 Employees

Company overview

Headquarters	Gaston Geenslaan 1, Leuven, 3001, BE
Phone number	+3216751310
Website	oxurion.com
NAICS	541714
SIC	807
Employees	21-50
Socials

Key Contacts at Oxurion NV

Pascal Ghoson

Chief Executive Officer

Alfred Aronson

Director Human Resources

Oxurion NV Email Formats

Oxurion NV uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@oxurion.com), used 50% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@oxurion.com	50%
{first name}.{last name}	john.doe@oxurion.com	33.3%
{first initial}.{second initial}{last name}	j.odoe@oxurion.com	16.7%

About Oxurion NV

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Oxurion NV revenue & valuation

Annual revenue	$3,124
Revenue per employee	$1,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$9,996
Total funding	$483,400